Drug intelligence / Profile preview

carboplatin + gemcitabine + mifepristone

Development stage: Unknown
Lead developer: Johnson Matthey
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy regimen consisting of carboplatin (a platinum-based alkylating agent), gemcitabine (a nucleoside analog), and mifepristone (a glucocorticoid receptor antagonist). This investigational combination has been studied in phase I clinical trials for advanced breast cancer and recurrent or persistent ovarian cancer. Preclinical studies suggest that mifepristone may enhance the efficacy of carboplatin and gemcitabine by blocking glucocorticoid receptor activation, which can inhibit chemotherapy-induced cell death.

Targets

DNAPR (Progesterone receptor)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on carboplatin + gemcitabine + mifepristone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + gemcitabine + mifepristone.

Explore the full profile